Alison M Boyce
National Institute of Dental and Craniofacial Research (NIDCR)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alison M Boyce as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:04 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07541209 · Safety and Efficacy of PTH-IANational Institute of Dental and Craniofacial Research (NIDCR) · recruiting · Jansen's Metaphyseal Chondrodysplasia · principal investigator
- Ph2NCT05509595 · Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous DysplasiaNational Institute of Dental and Craniofacial Research (NIDCR) · completed · Fibrous Dysplasia Of Bone · principal investigator
- Ph2NCT05419050 · Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous DysplasiaNational Institute of Dental and Craniofacial Research (NIDCR) · completed · Fibrous Dysplasia · principal investigator
- Ph2NCT03571191 · Denosumab Treatment for Fibrous DysplasiaNational Institute of Dental and Craniofacial Research (NIDCR) · active not recruiting · Bone Diseases, Pain · principal investigator
- N/ANCT00001727 · Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright SyndromeNational Institute of Dental and Craniofacial Research (NIDCR) · recruiting · McCune-Albright Syndrome · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Metabolic Bone Disorders UnitZIADE000758 · NIDCR · NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH · fiscal years 2021 to 2025 · $2,314,275 awarded in 2025Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:04 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone.J Clin Endocrinol Metab · 2014109 citationsRCR 5.0
- Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease Burden.J Bone Miner Res · 201981 citationsRCR 4.4
- Age-Related Changes and Effects of Bisphosphonates on Bone Turnover and Disease Progression in Fibrous Dysplasia of Bone.J Bone Miner Res · 201980 citationsRCR 5.3
- Scoliosis in Fibrous Dysplasia/McCune-Albright Syndrome: Factors Associated With Curve Progression and Effects of Bisphosphonates.J Bone Miner Res · 201828 citationsRCR 1.7
- RANKL inhibition reduces lesional cellularity and Gαs variant expression and enables osteogenic maturation in fibrous dysplasia.Bone Res · 202421 citationsRCR 4.0
- Safety and Efficacy of Moderate-dose Denosumab in Fibrous Dysplasia: Observational Results From a Phase 2 Clinical Trial.J Clin Endocrinol Metab · 20259 citationsRCR 4.2